阿帕替尼治疗进展性碘难治分化型甲状腺癌II期试验长期结果
该开放标签探索性II期试验评估阿帕替尼治疗进展性碘难治分化型甲状腺癌的长期疗效与安全性。结果显示客观缓解率80%、疾病控制率95%,中位无进展生存18.4个月,中位总生存51.6个月,BRAFV600E突变者无进展生存更长,安全性可耐受。
要点
- 阿帕替尼在进展性RAIR-DTC中客观缓解率80%、疾病控制率95%。
- 中位PFS 18.4个月,中位OS 51.6个月。
- BRAFV600E突变者中位PFS未达到,优于野生型9.2个月。
核心结论
- 阿帕替尼在进展性RAIR-DTC中显示持续疗效和可耐受的安全性,是有前景的治疗选择。
研究设计与样本
- 开放标签、探索性II期临床试验,纳入进展性RAIR-DTC患者,阿帕替尼每日一次口服至疾病进展、不可管理毒性、退出或死亡。
- 主要终点为客观缓解率和疾病控制率,同时评估PFS、OS、缓解持续时间、长期安全性及肿瘤基因型与PFS的关系。
主要发现
- 客观缓解率为80%,疾病控制率为95%。
- 总体中位PFS为18.4个月(95% CI,9.2-36.8个月),中位OS为51.6个月(95% CI,29.2-未达到[NR])。
- 18例可评估患者中10例有BRAFV600E突变,其mPFS未达到,优于BRAF野生型的9.2个月(P=0.002)。
- 最常见不良事件包括手足皮肤反应(19/20)、蛋白尿(18/20)和高血压(16/20)。
关键数值与推荐
- 客观缓解率80%,疾病控制率95%。
- 总体中位PFS 18.4个月(95% CI,9.2-36.8个月)。
- 总体中位OS 51.6个月(95% CI,29.2-未达到[NR])。
- BRAFV600E突变者mPFS未达到,BRAF野生型9.2个月,P=0.002。
临床怎么用
- 阿帕替尼可作为进展性RAIR-DTC的潜在治疗选择,需关注手足皮肤反应、蛋白尿和高血压等不良事件。
- BRAFV600E突变状态可能有助于预判阿帕替尼的PFS获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Radioiodine refractory differentiated thyroid cancer (RAIR-DTC) has been a global challenge due to its poor prognosis and limited treatment options. OBJECTIVE: We report here the long-term results of the phase II clinical trial of apatinib, an anti-angiogenic tyrosine kinase inhibitor, for RAIR-DTC. METHODS: This was an open-label, exploratory phase II clinical trial among progressive RAIR-DTC patients. Apatinib treatment was given once daily until disease progression, unmanageable toxicity, withdrawal, or death. The primary end points were objective response rate (ORR) and disease control rate (DCR). Progression-free survival (PFS), overall survival (OS), duration of response, long-term safety, and the association between patients with different tumor genotype (BRAFV600E and TERT promotor mutation) and their PFS rates were also assessed. RESULTS: The ORR was 80%, and the DCR was 95%. The overall median PFS was 18.4 months (95% CI, 9.2-36.8 months) and the median OS was 51.6 months (95% CI, 29.2-not reached [NR]). Patients with BRAFV600E mutation (10 of 18 evaluated) had a longer median PFS compared with patients with BRAF wild-type (NR vs 9.2 months; P = 0.002). The most common adverse events included palmar-plantar erythrodysesthesia syndrome (19/20), proteinuria (18/20), and hypertension (16/20). CONCLUSION: In this long-term evaluation, apatinib displayed sustainable efficacy and tolerable safety profile, warranting it as a promising treatment option for progressive RAIR-DTC.
引用
- Lin YS, Zhang X, Wang C, et al. Long-Term Results of a Phase II Trial of Apatinib for Progressive Radioiodine Refractory Differentiated Thyroid Cancer. J Clin Endocrinol Metab. 2021. PMID: 33769497. doi:10.1210/clinem/dgab196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。